Show simple item record

The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies

dc.contributor.authorShu, Xiao-Ou
dc.contributor.authorZheng, Wei
dc.date.accessioned2019-10-09T15:22:41Z
dc.date.available2019-10-09T15:22:41Z
dc.date.issued2019-06
dc.identifier.citationBing Yu, Krista A Zanetti, Marinella Temprosa, Demetrius Albanes, Nathan Appel, Clara Barrios Barrera, Yoav Ben-Shlomo, Eric Boerwinkle, Juan P Casas, Clary Clish, Caroline Dale, Abbas Dehghan, Andriy Derkach, A Heather Eliassen, Paul Elliott, Eoin Fahy, Christian Gieger, Marc J Gunter, Sei Harada, Tamara Harris, Deron R Herr, David Herrington, Joel N Hirschhorn, Elise Hoover, Ann W Hsing, Mattias Johansson, Rachel S Kelly, Chin Meng Khoo, Mika Kivimäki, Bruce S Kristal, Claudia Langenberg, Jessica Lasky-Su, Deborah A Lawlor, Luca A Lotta, Massimo Mangino, Loïc Le Marchand, Ewy Mathé, Charles E Matthews, Cristina Menni, Lorelei A Mucci, Rachel Murphy, Matej Oresic, Eric Orwoll, Jennifer Ose, Alexandre C Pereira, Mary C Playdon, Lucilla Poston, Jackie Price, Qibin Qi, Kathryn Rexrode, Adam Risch, Joshua Sampson, Wei Jie Seow, Howard D Sesso, Svati H Shah, Xiao-Ou Shu, Gordon C S Smith, Ulla Sovio, Victoria L Stevens, Rachael Stolzenberg-Solomon, Toru Takebayashi, Therese Tillin, Ruth Travis, Ioanna Tzoulaki, Cornelia M Ulrich, Ramachandran S Vasan, Mukesh Verma, Ying Wang, Nick J Wareham, Andrew Wong, Naji Younes, Hua Zhao, Wei Zheng, Steven C Moore, The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies, American Journal of Epidemiology, Volume 188, Issue 6, June 2019, Pages 991–1012, https://doi.org/10.1093/aje/kwz028en_US
dc.identifier.issn0002-9262
dc.identifier.urihttp://hdl.handle.net/1803/9578
dc.descriptionOnly Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://academic.oup.com/aje/article/188/6/991/5341178en_US
dc.description.abstractThe Consortium of Metabolomics Studies (COMETS) was established in 2014 to facilitate large-scale collaborative research on the human metabolome and its relationship with disease etiology, diagnosis, and prognosis. COMETS comprises 47 cohorts from Asia, Europe, North America, and South America that together include more than 136,000 participants with blood metabolomics data on samples collected from 1985 to 2017. Metabolomics data were provided by 17 different platforms, with the most frequently used labs being Metabolon, Inc. (14 cohorts), the Broad Institute (15 cohorts), and Nightingale Health (11 cohorts). Participants have been followed for a median of 23 years for health outcomes including death, cancer, cardiovascular disease, diabetes, and others; many of the studies are ongoing. Available exposure-related data include common clinical measurements and behavioral factors, as well as genome-wide genotype data. Two feasibility studies were conducted to evaluate the comparability of metabolomics platforms used by COMETS cohorts. The first study showed that the overlap between any 2 different laboratories ranged from 6 to 121 metabolites at 5 leading laboratories. The second study showed that the median Spearman correlation comparing 111 overlapping metabolites captured by Metabolon and the Broad Institute was 0.79 (interquartile range, 0.56-0.89).en_US
dc.description.sponsorshipD.A.L. has received support from Roche Diagnostics and Medtronic for research unrelated to this paper. B.S.K. is the inventor of general metabolomics-related intellectual property that has been licensed to Metabolon via Weill Medical College of Cornell University and for which he receives royalty payments via Weill Medical College of Cornell University. He also consults for and has a small equity interest in the company. Metabolon has no rights or proprietary access to the research results presented and/or new intellectual property generated under these grants/studies. B.S.K.'s interests were reviewed by the Brigham and Women's Hospital and Partners Healthcare in accordance with their institutional policy. Accordingly, upon review, the institution determined that B.S.K.'s financial interest in Metabolon does not create a significant financial conflict of interest with this research. The addition of this statement where appropriate was explicitly requested and approved by Brigham and Women's Hospital.en_US
dc.language.isoen_USen_US
dc.publisherAMERICAN JOURNAL OF EPIDEMIOLOGYen_US
dc.rightsThis work is written by (a) US Government employee(s) and is in the public domain in the US.
dc.source.urihttps://academic.oup.com/aje/article/188/6/991/5341178
dc.subjectcanceren_US
dc.subjectcohorten_US
dc.subjectdiabetesen_US
dc.subjectgeneticsen_US
dc.subjectheart diseaseen_US
dc.subjectmetabolomicsen_US
dc.subjectprospectiveen_US
dc.subjectprostate-cancer risken_US
dc.subjectnational death indexen_US
dc.subjectmale meat-eatersen_US
dc.subjectbody-mass indexen_US
dc.subjectcikirectak-canceren_US
dc.subjectbeta-caroteneen_US
dc.subjectbreast canceren_US
dc.subjectosteoporotic fracturesen_US
dc.subjectatherosclerosis risken_US
dc.subjectmetabolite profilesen_US
dc.subject.lcshcanceren_US
dc.subject.lcshgeneticsen_US
dc.titleThe Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studiesen_US
dc.typeArticleen_US
dc.identifier.doiD.A.L. has received support from Roche Diagnostics and Medtronic for research unrelated to this paper. B.S.K. is the inventor of general metabolomics-related intellectual property that has been licensed to Metabolon via Weill Medical College of Cornell University and for which he receives royalty payments via Weill Medical College of Cornell University. He also consults for and has a small equity interest in the company. Metabolon has no rights or proprietary access to the research results presented and/or new intellectual property generated under these grants/studies. B.S.K.'s interests were reviewed by the Brigham and Women's Hospital and Partners Healthcare in accordance with their institutional policy. Accordingly, upon review, the institution determined that B.S.K.'s financial interest in Metabolon does not create a significant financial conflict of interest with this research. The addition of this statement where appropriate was explicitly requested and approved by Brigham and Women's Hospital.


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record